Expertise in
1
conditions

Daniel Heudobler

Franz Josef Strauß Allee 11, 
Regensburg, BY, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Franz Josef Strauß Allee 11, 
Regensburg, BY, DE 

Overview

Daniel Heudobler practices practicing medicine in Regensburg, Germany.

Mr. Heudobler is highly rated in 1 condition, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Acute Myeloid Leukemia (AML), and Cerebral Hypoxia.

He is actively involved in clinical research, co-authoring 53 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Franz Josef Strauß Allee 11, Regensburg, BY 93053, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: May 13, 2026
Intervention Type: Biological, Device, Drug
Study Drugs: IMA203 Product, Atezolizumab
Study Phase: Phase 1/Phase 2
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Device, Drug
Study Drug: IMA202
Study Phase: Phase 1
View 1 Less Clinical Trial

53 Total Publications

Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.
Journal: Nature medicine
Published: June 19, 2026

Frequently Asked Questions about Daniel Heudobler

Is Daniel Heudobler a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Daniel Heudobler is classified as an Advanced expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Daniel Heudobler participate in research or clinical trials?

Yes. Daniel Heudobler has published 53 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Daniel Heudobler's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Heudobler's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile